CanDapi
Dry Powder Inhaler
Health Tech & Life Sciences
Non Active, Sep 2025 ceased to operate
Company Overview
Snapshot
Founded in March 2022 by Amnon Kritzman and Amnon Kritzman Kidron, CanDapi operates with 1–10 employees. The company has raised $3.5 million across one funding round from two investors. In July 2022, CanDapi secured seed funding from the Israel Innovation Authority.
Business overview
CanDapi is a Health Tech & Life Sciences company focused on developing a breakthrough dry powder inhaler for delivering medications and cannabinoids to the lungs. Its core product is designed to be versatile, suitable for various generic and systemic medical powder drugs, and user-friendly for all patients. The company operates within the Pharma & Medical Biotechnology sector, specifically targeting the Medical Cannabis and Drug Delivery markets.
Company Intelligence Q&A
- What is CanDapi's primary product?
- CanDapi's primary product is a dry powder inhaler designed for the delivery of medications and cannabinoids to the lungs. It is engineered to be suitable for various generic and systemic medical powder drugs.
- When was CanDapi founded?
- CanDapi was founded in March 2022.
- Who are the founders of CanDapi?
- CanDapi was founded by Amnon Kritzman and Amnon Kritzman Kidron.
- What is the current status of CanDapi?
- CanDapi is currently non-active and ceased to operate in September 2025.
- Which sector does CanDapi operate in?
- CanDapi operates in the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology, Medical Cannabis, and Drug Delivery.